Quantcast
Last updated on April 18, 2014 at 10:01 EDT

Latest Watson Stories

2012-01-12 15:00:00

PARSIPPANY, N.J., Jan. 12, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that it will host an Investor Meeting on January 24, 2012 in New York City. The meeting will begin at 8:00 a.m. Eastern Time and will be simultaneously webcast. At the meeting, the Company plans to provide a preliminary update on 2011 achievements as well as a business outlook for 2012 and beyond. Paul Bisaro, Watson's President...

2011-12-28 15:00:00

PARSIPPANY, N.J., Dec. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, announced today that Paul Bisaro, Watson's President and Chief Executive Officer, will provide an overview and update of the Company's business at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 7:30 am Pacific Standard Time (10:30 am Eastern Standard Time) at the Westin St. Francis in San Francisco, California. The...

2011-12-07 15:57:00

PARSIPPANY, N.J., Dec. 7, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that under a settlement with Teva Women's Health, Watson has launched Amethia® Lo (levonorgestrel/ethinyl estradiol (0.1mg/0.02mg) and ethinyl estradiol (0.01mg)) tablets, the generic equivalent of Teva Women's Health, Inc.'s LoSEASONIQUE®. Amethia® Lo tablets are indicated for the prevention of pregnancy. Terms of the...

2011-11-30 05:56:00

PARSIPPANY, N.J., Nov. 30, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson Pharmaceuticals, Inc., has launched an authorized generic version of LIPITOR®( )(atorvastatin calcium tablets) as part of an exclusive agreement with Pfizer Inc. Watson began shipping the product today. LIPITOR®( )is indicated as an adjunct to diet to reduce elevated total cholesterol, LDL, triglycerides and to increase HDL...

2011-11-29 07:53:00

PARSIPPANY, N.J., Nov. 29, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product. Watson is currently involved in patent litigation with Bayer concerning this product. Yaz(R)...

2011-11-16 16:46:00

PARSIPPANY, N.J., Nov. 16, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that a jury in the drug pricing litigation trial in the Kentucky Circuit Court for Franklin County rendered a verdict in favor of Watson on all counts in the litigation. Beginning in July 2002, the Company and certain of its subsidiaries, as well as numerous other pharmaceutical companies, were named as defendants in various states and federal court actions including the case decided...

2011-11-10 15:20:00

PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for morphine sulfate extended-release capsules USP, the generic equivalent of Actavis' Kadian®. Watson began shipping the product today. Kadian® is indicated to manage moderate to severe pain that continues...

2011-11-10 15:00:00

PARSIPPANY, N.J., Nov. 10, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the United States Court of Appeals for the Federal Circuit affirmed the district court's June 16, 2011 denial of Duramed Pharmaceuticals, Inc.'s request for a preliminary injunction to prevent Watson from selling generic SEASONIQUE® (levonorgestrel/ethinyl estradiol (0.15 mg/0.03 mg) and ethinyl estradiol (0.01 mg)). Watson launched Amethia(TM)...

2011-10-31 07:59:00

BOSTON and CAMBRIDGE, Mass., Oct. 31, 2011 /PRNewswire/ -- IBM (NYSE: IBM) today will conduct a Watson symposium with Harvard Business School (HBS) and the Massachusetts Institute of Technology (MIT) Sloan School of Management. The event brings together some of the brightest academic minds to collaborate on the use of advanced analytics, like those powering Watson, to transform the way the world does business. Follow the event and share your thoughts at #IBMWatson on Twitter and the...

2011-10-28 16:29:00

PARSIPPANY, N.J., Oct. 28, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), today confirmed that the United States District Court for the District of Massachusetts has granted Momenta Pharmaceuticals, Inc. and Sandoz Inc.'s request for a preliminary injunction preventing Watson and Amphastar Pharmaceuticals, Inc. from marketing or selling Amphastar's Enoxaparin Sodium Injection, a generic equivalent to Sanofi-aventis' LOVENOX®. The Company said...